News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genesis Bioventures (GBIW) Announces Breast Cancer Marker Granted European Diagnostic and Therapeutic Patent Approval


6/19/2007 2:03:50 PM

LOS ANGELES--(BUSINESS WIRE)--Genesis Bioventures, Inc. (OTCBB:GBIW) announced today that Mammastatin, the breast cancer marker exclusively licensed to the Company by the University of Michigan, was granted an additional Patent from the European Patent Office for diagnostic and therapeutic uses. The Mammastatin technology is developed for use as the Mammastatin Serum Assay, a breast cancer risk assessment test developed by Biomedical Diagnostics, the Company’s subsidiary.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES